Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062034 | 0.85 | KMT2A (0.53) | P2RY12KMT2AMEN1MAPK1MAPT | |
| SCHEMBL5851166 | 0.82 | P2RY12 (0.61) | P2RY12KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5849182 | 0.82 | KMT2A (0.53) | P2RY12KMT2AMEN1MAPK1MAPT | |
| SCHEMBL5849512 | 0.80 | P2RY12 (0.85) | P2RY12KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL5849400 | 0.76 | P2RY12 (0.67) | P2RY12KMT2AMEN1MAPK1MAPT | |
| SCHEMBL5850896 | 0.75 | P2RY12 (0.80) | P2RY12KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL5851381 | 0.75 | P2RY12 (1.00) | P2RY12KMT2AMEN1MAPK1MAPT | |
| SCHEMBL5849656 | 0.72 | KMT2A (0.44) | P2RY12KMT2AMEN1MAPK1MAPT | |
| SCHEMBL5851617 | 0.72 | P2RY12 (0.82) | P2RY12KMT2AMEN1ALDH1A1 | |
| SCHEMBL5849659 | 0.72 | KMT2A (0.41) | P2RY12KMT2AMEN1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | P2RY12 111/4885KMT2A 1823/4885MEN1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.